COMPASS FINANCIAL MANAGEMENT LLC’s BridgeBio Pharma BBIO Stock Holding History

COMPASS FINANCIAL MANAGEMENT LLC’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.1K	Buy	+147	New	+$10.3K	﹤0.01%	1014

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

COMPASS FINANCIAL MANAGEMENT LLC's BBIO Position: Q2 2026 in Review

COMPASS FINANCIAL MANAGEMENT LLC opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 147 shares worth $12.1K. The stake represents ﹤0.01% of the portfolio and ranks #1014 among its holdings.

301 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

COMPASS FINANCIAL MANAGEMENT LLC held 147 shares of BridgeBio Pharma worth $12.1K as of Q2 2026.
BridgeBio Pharma was a new COMPASS FINANCIAL MANAGEMENT LLC position in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of COMPASS FINANCIAL MANAGEMENT LLC's portfolio in Q2 2026, its #1014 holding.
301 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on COMPASS FINANCIAL MANAGEMENT LLC's 13F filing for Q2 2026, filed 12 Aug 2026.